{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T07:27:54Z","timestamp":1725694074921},"publisher-location":"Vienna","reference-count":51,"publisher":"Springer Vienna","isbn-type":[{"type":"print","value":"9783211828915"},{"type":"electronic","value":"9783709174944"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1996]]},"DOI":"10.1007\/978-3-7091-7494-4_8","type":"book-chapter","created":{"date-parts":[[2012,7,28]],"date-time":"2012-07-28T16:54:42Z","timestamp":1343494482000},"page":"85-93","source":"Crossref","is-referenced-by-count":1,"title":["The clinical potential of Deprenyl in neurologic and psychiatric disorders"],"prefix":"10.1007","author":[{"given":"W.","family":"Kuhn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Th.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"8_CR1","first-page":"191","volume":"45","author":"Y Agid","year":"1986","unstructured":"Agid Y, Javoy-Agid F, Ruberg M, et al (1986) Progressive supranuclear palsy: anatomoclinical and biochemical considerations. Adv Neurol 45: 191\u2013206","journal-title":"Adv Neurol"},{"key":"8_CR2","first-page":"109","volume":"1","author":"A Agnoli","year":"1990","unstructured":"Agnoli A, Martucci N, Fabbrini G, et al (1990) Monoamine oxidase and dementia: treatment with an inhibitor of MAO-B activity. Dementia 1: 109\u2013114","journal-title":"Dementia"},{"key":"8_CR3","first-page":"2","volume":"4","author":"R Baldessarini","year":"1979","unstructured":"Baldessarini RJ (1979) Neurological toxicology of antipyschotic drugs. McLean Hosp J 4:2\u201319","journal-title":"McLean Hosp J"},{"issue":"1\u20134","key":"8_CR4","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3109\/00207459309000603","volume":"71","author":"CR Bamford","year":"1993","unstructured":"Bamford CR, Montgomery EB Jr, Munoz JE, et al (1993) Postpolio syndrome-response to deprenyl (selegiline). Int J Neurosci 71(1\u20134): 183\u2013188","journal-title":"Int J Neurosci"},{"key":"8_CR5","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/BF00690936","volume":"91","author":"L Bucci","year":"1987","unstructured":"Bucci L (1987) The negative symptoms of schizophrenia and the monoamine oxidase inhibitors. Psychopharmacology 91: 104\u2013108","journal-title":"Psychopharmacology"},{"issue":"11","key":"8_CR6","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/j.1532-5415.1993.tb07306.x","volume":"41","author":"WJ Burke","year":"1993","unstructured":"Burke WJ, Roccaforte WH, Wengel SP, et al (1993) L-Deprenyl in the treatment of mild dementia of the Alzheimer type: results of a IS-month trial. J Am Geriatr Soc 41(11): 1219\u2013225","journal-title":"J Am Geriatr Soc"},{"key":"8_CR7","first-page":"306","volume":"12","author":"N Campi","year":"1990","unstructured":"Campi N, Todeschini GP, Scarzella L (1990) Selegiline versus L-acetylcarnitine in the treatment of Alzheimer type dementia. Clin Ther 12: 306\u2013314","journal-title":"Clin Ther"},{"key":"8_CR8","unstructured":"Chouinard G, Jones BD, Annable L (1980) L-dopa in neuroleptic induced extrapyramidal symptoms. 35th Annual Convention of Society of Biological Psychiatry of USA, Boston"},{"key":"8_CR9","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/ana.410260518","volume":"26","author":"G Cohen","year":"1989","unstructured":"Cohen G, Spina MB (1989) Deprenyl suppresses the oxidant stress associated with increased dopamine turn-over. Ann Neurol 26: 689\u2013690","journal-title":"Ann Neurol"},{"key":"8_CR10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1136\/bmj.280.6207.66","volume":"280","author":"T Crow","year":"1980","unstructured":"Crow TJ (1980) Molecular pathology of schizophrenia: more than one disease process? Br Med J 280: 66\u201368","journal-title":"Br Med J"},{"key":"8_CR11","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1055\/s-2007-1014356","volume":"26","author":"GR Gewirtz","year":"1993","unstructured":"Gewirtz GR, Sharif Z, Cadet JL, Sarti P, Gorman JM (1993) Selegiline for neuroleptic-induced Parkinsonism. Pharmacopsychiat 26: 128\u2013129","journal-title":"Pharmacopsychiat"},{"key":"8_CR12","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/0006-3223(93)90119-X","volume":"33","author":"DC Goff","year":"1993","unstructured":"Goff DC, Renshaw PF, Sarid-Segal O, et al (1993) A placebo-controlled trial of selegiline (L-deprenyl) in the treatment of tardive dyskinesia. Biol Psychiatry 33: 700\u2013706","journal-title":"Biol Psychiatry"},{"key":"8_CR13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1600-0404.1991.tb05020.x","volume":"136","author":"EH Heinonen","year":"1991","unstructured":"Heinonen EH, Lammintausta R (1991) A review of the pharmacology of selegiline. Acta Neurol Scand 136 [Suppl]: 44\u201359","journal-title":"Acta Neurol Scand"},{"key":"8_CR14","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1212\/WNL.44.11.2095","volume":"44","author":"C Hublin","year":"1994","unstructured":"Hublin C, Partinen M, Heinonen EH, Punkka P, Salmi T (1994) Selegiline in the treatment of narcolepsy. Neurology 44: 2095\u20132101","journal-title":"Neurology"},{"key":"8_CR15","first-page":"7","volume":"58","author":"J Jankovic","year":"1992","unstructured":"Jankovic J (1992) Diagnosis and classification of tics and Tourette Syndrome. Adv Neurol 58: 7\u201314","journal-title":"Adv Neurol"},{"key":"8_CR16","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1001\/archneur.1993.00540030052014","volume":"50","author":"J Jankovic","year":"1993","unstructured":"Jankovic J (1993) Deprenyl in attention deficit associated with Tourette\u2019s syndrome. Arch Neurol 50:286\u2013288","journal-title":"Arch Neurol"},{"key":"8_CR17","first-page":"237","volume":"41","author":"SS Jossan","year":"1994","unstructured":"Jossan SS, Ekblom J, Gudjonsson O, Hagbarth KE (1994) Double blind cross over trial with deprenyl in amyotrophic lateral sclerosis. J Neural Transm [Suppl] 41: 237\u2013241","journal-title":"J Neural Transm [Suppl]"},{"key":"8_CR18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1600-0404.1989.tb01787.x","volume":"126","author":"J Knoll","year":"1989","unstructured":"Knoll J (1989) The pharmacology of selegiline ((\u2212)deprenyl). New aspects. Acta Neurol Scand 126 [Suppl]: 83\u201391","journal-title":"Acta Neurol Scand"},{"key":"8_CR19","first-page":"393","volume-title":"Monoamine oxidase \u2014 new vistas","author":"J Knoll","year":"1972","unstructured":"Knoll J, Magyar K (1972) Some puzzling pharmacological effects of monoamine oxidase inhibitors. In: Costa E, Sandler M (eds) Monoamine oxidase \u2014 new vistas. Raven Press, New York, pp 393\u2013408"},{"issue":"8","key":"8_CR20","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/j.1526-4610.1992.hed3208416.x","volume":"32","author":"A Kuritzky","year":"1992","unstructured":"Kuritzky A, Zoldan Y, Melamed E (1992) Selegiline, a MAO-B inhibitor, is not effective in the prophylaxis of migraine without aura \u2014 an open study. Headache 32(8): 416","journal-title":"Headache"},{"key":"8_CR21","first-page":"303","volume":"4","author":"P Lavie","year":"1980","unstructured":"Lavie P, Wajsbort J, Youdim MBH (1980) Deprenyl does not cause insomnia in parkinsonian patients. Commun Psychopharmacol 4: 303\u2013307","journal-title":"Commun Psychopharmacol"},{"key":"8_CR22","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1001\/archpsyc.1991.01810360061009","volume":"48","author":"J Lohr","year":"1991","unstructured":"Lohr JB (1991) Oxygen radicals and neuropsychiatric illness. Arch Gen Pschiatry 48: 1097\u20131106","journal-title":"Arch Gen Pschiatry"},{"key":"8_CR23","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1159\/000116655","volume":"31","author":"A Mangoni","year":"1991","unstructured":"Mangoni A, Grassi MP, Frattola L, Piolti R, Bassi S, Motta A, Marcone A, Smirne S (1991) Effects of a MAO-B inhibitor in the treatment of Alzheimer\u2019s disease. Eur Neurol 31: 100\u2013107","journal-title":"Eur Neurol"},{"key":"8_CR24","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/0024-3205(80)90350-1","volume":"26","author":"J Mann","year":"1980","unstructured":"Mann J, Gershon S (1980) L-Deprenyl, a selective monoamine oxidase type-B inhibitor in endogenous depression. Life Sci 26: 877\u2013882","journal-title":"Life Sci"},{"key":"8_CR25","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/00004714-198202000-00008","volume":"2","author":"JJ Mann","year":"1982","unstructured":"Mann JJ, Frances A, Kaplan RD, et al (1982) The relative efficacy of 1-Deprenyl, a selective monoamine oxidase type B inhibitor, in endogenous and nonendogenous depression. J Clin Psychopharmacol 2(sn1): 54\u201357","journal-title":"J Clin Psychopharmacol"},{"key":"8_CR26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/archpsyc.1989.01810010047007","volume":"46","author":"JJ Mann","year":"1989","unstructured":"Mann JJ, Aarons SF, Wilner PJ, Keilp JG, Sweeney JA, Pearlstein T, Frances AJ, Kocsis JH, Brown RP (1989) A controlled study of the antidepressant efficacy and side effects of (\u2212)-deprenyl: a selective monoamine oxidase inhibitor. Arch Gen Psychiatry 46: 45\u201350","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"8_CR27","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/00002826-199508000-00002","volume":"18","author":"G Mayer","year":"1995","unstructured":"Mayer G, Ewert Meier K, Klinik Hephata (1995) Selegiline Hydrochloride treatment in narcolepsy. A double-blind, placebo-controlled study. Clin Neuropharmacol 18\/4: 306\u2013319","journal-title":"Clin Neuropharmacol"},{"key":"8_CR28","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/BF00863772","volume":"241","author":"L Mazzini","year":"1994","unstructured":"Mazzini L, Testa D, Balzarini C, Mora G (1994) An open-randomized clinical trial of selegiline in amyotrophic lateral sclerosis. J Neurol 241: 223\u2013227","journal-title":"J Neurol"},{"key":"8_CR29","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/00004714-198612000-00002","volume":"6","author":"HY Meltzer","year":"1986","unstructured":"Meltzer HY, Sommers AA, Luchins DJ (1986) The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizphrenia. J Clin Psychopharmacol 6: 329\u2013338","journal-title":"J Clin Psychopharmacol"},{"key":"8_CR30","first-page":"171","volume-title":"Monoamine oxidase inhibitors: the state of the art","author":"N Mendis","year":"1981","unstructured":"Mendis N, Pare CMB, Sandler M, et al (1981) Deprenyl in the treatment of depression. In: Youdim MBH, Paykel ES (eds) Monoamine oxidase inhibitors: the state of the art. John Wiley and Sons, Chichester, pp 171\u2013176"},{"key":"8_CR31","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1192\/bjp.142.5.508","volume":"142","author":"J Mendlewicz","year":"1983","unstructured":"Mendlewicz J, Youdim MBH (1983) L-Deprenyl, a selective monoamine oxidase type B inhibitor, and the treatment of depression: a double blind evaluation. Br J Psychiatry 142: 508\u2013511","journal-title":"Br J Psychiatry"},{"key":"8_CR32","unstructured":"Mitchell JD, Houghton E, Kilshow J, et al (1993) Free radicals, sporadic motor neurone disease and selegiline. Symposium on Neuroprotection and clinical trials in MND\/ ALS, Paris (Abstract)"},{"key":"8_CR33","first-page":"315","volume":"12","author":"A Monteverde","year":"1990","unstructured":"Monteverde A, Gnemmi P, Rossi F, Monteverde A (1990) Selegiline in the treatment of mild to moderate Alzheimer type dementia. Clin Ther 12: 315\u2013322","journal-title":"Clin Ther"},{"key":"8_CR34","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/BF00307697","volume":"80","author":"S Nakamura","year":"1990","unstructured":"Nakamura S, Kawamata T, Akiguchi I, Kameyama M, Nakamura N, Kimura H (1990) Expression of monoamine oxidase B activity in astrocytes of senile plaques. Acta Neuropathol 80: 419\u2013425","journal-title":"Acta Neuropathol"},{"issue":"4","key":"8_CR35","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1097\/00002826-199308000-00006","volume":"16","author":"KA Nieforth","year":"1993","unstructured":"Nieforth KA, Golbe LI (1993) Retrospective study of drug response in 87 patients with progressive supranuclear palsy. Clin Neuropharmacol 16\/4: 338\u2013346","journal-title":"Clin Neuropharmacol"},{"key":"8_CR36","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/0278-5846(86)90023-0","volume":"10","author":"L Oreland","year":"1986","unstructured":"Oreland L, Gottfries CG (1986) Brain and brain monoamine oxidase in aging and in dementia of Alzheimer\u2019s type. Prog Neuropsychopharmacol Biol Psychiatry 10: 533\u2013540","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"8_CR37","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1055\/s-2007-1019488","volume":"16","author":"A Perenyi","year":"1983","unstructured":"Perenyi A, Bagdy G, Arato M (1983) An early phase II trial with l-deprenyl for the treatment of neuroleptic-induced Parkinsonism. Pharmacopsychiat 16: 143\u2013146","journal-title":"Pharmacopsychiat"},{"key":"8_CR38","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0165-1781(92)90082-E","volume":"42","author":"A Perenyi","year":"1992","unstructured":"Perenyi A, Goswami U, Frecska E, Arata M, Bela A (1992) L-Deprenyl in treating negative symptoms of schizophrenia. Psychiatry Res 42: 189\u2013191","journal-title":"Psychiatry Res"},{"key":"8_CR39","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/00002826-199004000-00004","volume":"13","author":"GL Piccinin","year":"1990","unstructured":"Piccinin GL, Finali G, Piccarilli M (1990) Neuropsychological effects of L-deprenyl in Alzheimer\u2019s dementia. Clin Neuropharmacol 13: 147\u2013163","journal-title":"Clin Neuropharmacol"},{"key":"8_CR40","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1001\/archpsyc.1984.01790190051006","volume":"41","author":"FM Quitkin","year":"1984","unstructured":"Quitkin FM, Liebowitz MR, Stewart JW, McGrath PJ, Harrison W, Rabkin JG, Markowitz J, Davies SO (1984) L-Deprenyl in a typical depressives. Arch Gen Psychiatry 41: 777\u2013781","journal-title":"Arch Gen Psychiatry"},{"key":"8_CR41","unstructured":"Quitkin FM, Liebowitz MR, Stewart JW, et al (1985) Deprenyl in atypical depressives. I. Clinical efficacy. Proceedings of the International Symposium in Deprenyl. Chinoin, Budapest, pp 115\u2013119"},{"issue":"5","key":"8_CR42","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/sleep\/10.5.491","volume":"10","author":"SE Roselar","year":"1987","unstructured":"Roselar SE, Langdon N, Lock CB, Jenner P, Parkes JD (1987) Selegiline in narcolepsy. Sleep 10(5): 491\u2013495","journal-title":"Sleep"},{"key":"8_CR43","doi-asserted-by":"crossref","unstructured":"Schachter M, Price PA, Parkes JD (1979) Deprenyl in narcolepsy. Lancet i: 831\u2013832","DOI":"10.1016\/S0140-6736(79)91357-6"},{"key":"8_CR44","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1176\/ajp.150.2.321","volume":"150","author":"LS Schneider","year":"1993","unstructured":"Schneider LS, Olin JT, Pawluczyk S (1993) A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer\u2019s disease. Am J Psychiatry 150: 321\u2013323","journal-title":"Am J Psychiatry"},{"key":"8_CR45","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1001\/archpsyc.1994.03950080019003","volume":"51","author":"T Sunderland","year":"1994","unstructured":"Sunderland T, Cohen R, Molchan S, et al (1994) High dose selegiline in treatmentresistant older depressive patients. Arch Gen Psychiatry 51: 607\u2013615","journal-title":"Arch Gen Psychiatry"},{"key":"8_CR46","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1001\/archpsyc.1987.01800170041007","volume":"44","author":"PN Tariot","year":"1987","unstructured":"Tariot PN, Cohen R, Sunderland T, et al (1987a) L-Deprenyl in Alzheimer\u2019s disease. Arch Gen Psychiatry 44: 427\u2013433","journal-title":"Arch Gen Psychiatry"},{"key":"8_CR47","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/BF00216016","volume":"91","author":"PN Tariot","year":"1987","unstructured":"Tariot PN, Sunderland T, Weingartner H, et al (1987b) Cognitive effects of L-deprenyl in Alzheimer\u2019s disease. Psychopharmcology 91: 489\u2013495","journal-title":"Psychopharmcology"},{"key":"8_CR48","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1002\/mds.870080506","volume":"8","author":"W Tatton","year":"1993","unstructured":"Tatton WG (1993) Selegiline can mediate neuronal rescue rather than neuronal protection. Mov Disord 8: 520\u2013530","journal-title":"Mov Disord"},{"key":"8_CR49","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/BF00435308","volume":"70","author":"C Thornton","year":"1980","unstructured":"Thornton C, Dore CJ, Elsworth JD, Herbert M, Stern GM (1980) The effect of Deprenyl, a selective monoamine oxidase B inhibitor, on sleep and mood in man. Psychopharmcol 70: 163\u2013166","journal-title":"Psychopharmcol"},{"key":"8_CR50","unstructured":"Tringer L, Haits G, Varga E (1971) The effect of L-E-280 (L-phenylisopropyl-methyl-propinylamine) in depression. Soc Pharmacol Hungarica, Budapest, pp 111\u2013113"},{"key":"8_CR51","first-page":"289","volume":"23","author":"E Varga","year":"1967","unstructured":"Varga E, Tringer L (1967) Clinical trial of a new type of promptly acting psychoenergetic agent (Phenyl-isopropyl-methyl propinyl-HCL, E 250). Acta Med Acad Sci Hung 23: 289\u2013295","journal-title":"Acta Med Acad Sci Hung"}],"container-title":["Deprenyl \u2014 Past and Future"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-7091-7494-4_8.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T04:36:25Z","timestamp":1606106185000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-7091-7494-4_8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996]]},"ISBN":["9783211828915","9783709174944"],"references-count":51,"URL":"https:\/\/doi.org\/10.1007\/978-3-7091-7494-4_8","relation":{},"subject":[],"published":{"date-parts":[[1996]]}}}